Literature DB >> 18996182

Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression.

Eric V Yang1, Seung-jae Kim, Elise L Donovan, Min Chen, Amy C Gross, Jeanette I Webster Marketon, Sanford H Barsky, Ronald Glaser.   

Abstract

Studies suggest that stress can be a co-factor for the initiation and progression of cancer. The catecholamine stress hormone, norepinephrine (NE), may influence tumor progression by modulating the expression of factors implicated in angiogenesis and metastasis. The goal of this study was to examine the influence of NE on the expression of VEGF, IL-8, and IL-6 by the human melanoma cell lines, C8161, 1174MEL, and Me18105. Cells were treated with NE and levels of VEGF, IL-8, and IL-6 were measured using ELISA and real-time PCR. The expression of beta-adrenergic receptors (beta-ARs) mRNA and protein were also assessed. Finally, immunohistochemistry was utilized to examine the presence of beta1- and beta2-AR in primary and metastatic human melanoma biopsies. We show that NE treatment upregulated production of VEGF, IL-8, and IL-6 in C8161 cells and to a lesser extent 1174MEL and Me18105 cells. The upregulation was associated with induced gene expression. The effect on C8161 cells was mediated by both beta1- and beta2-ARs. Furthermore, 18 of 20 melanoma biopsies examined expressed beta2-AR while 14 of 20 melanoma biopsies expressed beta1-AR. Our data support the hypothesis that NE can stimulate the aggressive potential of melanoma tumor cells, in part, by inducing the production VEGF, IL-8, and IL-6. This line of research further suggests that interventions targeting components of the activated sympathetic-adrenal medullary (SAM) axis, or the utilization of beta-AR blocking agents, may represent new strategies for slowing down the progression of malignant disease and improving cancer patients' quality of life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18996182      PMCID: PMC2652747          DOI: 10.1016/j.bbi.2008.10.005

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  54 in total

1.  Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers.

Authors:  K Masur; B Niggemann; K S Zanker; F Entschladen
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

2.  Biochemical characterization of beta2-adrenergic receptor dimers and oligomers.

Authors:  Ali Salahpour; Hélène Bonin; Suparna Bhalla; Ulla Petäjä-Repo; Michel Bouvier
Journal:  Biol Chem       Date:  2003-01       Impact factor: 3.915

3.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

Review 4.  The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology.

Authors:  Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2003-02       Impact factor: 7.217

5.  Restraint stress alters the expression of interleukin-1 and keratinocyte growth factor at the wound site: an in situ hybridization study.

Authors:  Ana M Mercado; Ning Quan; David A Padgett; John F Sheridan; Phillip T Marucha
Journal:  J Neuroimmunol       Date:  2002-08       Impact factor: 3.478

6.  VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course.

Authors:  S Osella-Abate; P Quaglino; P Savoia; C Leporati; A Comessatti; M G Bernengo
Journal:  Melanoma Res       Date:  2002-08       Impact factor: 3.599

7.  Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells.

Authors:  T L Drell; J Joseph; K Lang; B Niggemann; K S Zaenker; F Entschladen
Journal:  Breast Cancer Res Treat       Date:  2003-07       Impact factor: 4.872

8.  Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up.

Authors:  Fawzy I Fawzy; Andrea L Canada; Nancy W Fawzy
Journal:  Arch Gen Psychiatry       Date:  2003-01

Review 9.  The role of chemokines in melanoma tumor growth and metastasis.

Authors:  Aimee S Payne; Lynn A Cornelius
Journal:  J Invest Dermatol       Date:  2002-06       Impact factor: 8.551

10.  Psychosocial stress augments tumor development through beta-adrenergic activation in mice.

Authors:  Hideo Hasegawa; Ikuo Saiki
Journal:  Jpn J Cancer Res       Date:  2002-07
View more
  113 in total

1.  β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.

Authors:  Stanley Lemeshow; Henrik Toft Sørensen; Gary Phillips; Eric V Yang; Sussie Antonsen; Anders H Riis; Gregory B Lesinski; Rebecca Jackson; Ronald Glaser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-20       Impact factor: 4.254

Review 2.  Biobehavioral factors and cancer progression: physiological pathways and mechanisms.

Authors:  Susan K Lutgendorf; Anil K Sood
Journal:  Psychosom Med       Date:  2011-10-21       Impact factor: 4.312

Review 3.  Antimicrobial anxiety: the impact of stress on antimicrobial immunity.

Authors:  Katherine A Radek
Journal:  J Leukoc Biol       Date:  2010-05-04       Impact factor: 4.962

4.  Role for catecholamines in tumor progression: possible use for β-blockers in the treatment of cancer.

Authors:  Eric V Yang
Journal:  Cancer Biol Ther       Date:  2010-07-06       Impact factor: 4.742

Review 5.  Sympathetic nervous system regulation of the tumour microenvironment.

Authors:  Steven W Cole; Archana S Nagaraja; Susan K Lutgendorf; Paige A Green; Anil K Sood
Journal:  Nat Rev Cancer       Date:  2015-09       Impact factor: 60.716

6.  Beta-adrenergic blocking drugs in breast cancer: a perspective review.

Authors:  Thomas I Barron; Linda Sharp; Kala Visvanathan
Journal:  Ther Adv Med Oncol       Date:  2012-05       Impact factor: 8.168

Review 7.  Biobehavioral influences on cancer progression.

Authors:  Erin S Costanzo; Anil K Sood; Susan K Lutgendorf
Journal:  Immunol Allergy Clin North Am       Date:  2011-02       Impact factor: 3.479

8.  Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice.

Authors:  Kathleen M Kokolus; Ying Zhang; Jeffrey M Sivik; Carla Schmeck; Junjia Zhu; Elizabeth A Repasky; Joseph J Drabick; Todd D Schell
Journal:  Oncoimmunology       Date:  2017-12-21       Impact factor: 8.110

9.  Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients.

Authors:  Monica E Lindgren; Christopher P Fagundes; Catherine M Alfano; Stephen P Povoski; Doreen M Agnese; Mark W Arnold; William B Farrar; Lisa D Yee; William E Carson; Carl R Schmidt; Janice K Kiecolt-Glaser
Journal:  Psychooncology       Date:  2012-12-17       Impact factor: 3.894

10.  Expression of β-adrenergic receptors in pediatric malignant brain tumors.

Authors:  Iacopo Sardi; Laura Giunti; Cecilia Bresci; Anna Maria Buccoliero; Duccio Degl'innocenti; Stefania Cardellicchio; Gianna Baroni; Francesca Castiglione; Martina DA Ros; Patrizio Fiorini; Sabrina Giglio; Lorenzo Genitori; Maurizio Aricò; Luca Filippi
Journal:  Oncol Lett       Date:  2012-10-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.